Alcoholism Clinical Trial
Official title:
A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury
Despite the body's natural healing during the first year after a head injury, many veterans
who have suffered even mild brain injuries find themselves easily upset or fearful as they
go about their daily lives. While these reactions to the world around them were easily
managed before the head injury, they now occur with little or no interruption and are
exceedingly difficult to manage. Such reactions include a sense of always being upset or
fearful that often makes it difficult to get along with family members, friends, coworkers,
and employers. This may lead to broken marriages, unemployment, and even homelessness.
Some people with head injuries try to manage their unmanageable moods by drinking alcohol
because it can create a sense of calm. However, alcohol's actions are short in duration.
Most find that they have to drink more and more for a similar calming effect, and they soon
become dependent on alcohol. This makes working and being part of their families even more
difficult.
To treat the unmanageable mood, we tried a medicine called valproate, one that eases mood
problems in people without head injury. We gave valproate to head injured persons with mood
problems in a "non-blinded" study where both the doctor and the patient knew that the
medicine was valproate and both were optimistic that it would work. In a small sample of
eighteen people, 85% found mood relief and most of those either stopped drinking alcohol or
drank much less than before. However, this might have been because both the doctor and
patient were hopeful that the medication would make the patient feel better or because the
medicine actually worked.
The only way to know for sure if the medicine works is to perform a study in which people
receive either valproate or a sugar pill while neither they nor their doctor know which one
they are taking. This is called a double blind study, as proposed here, and will involve
nearly three times as many head injured persons as the first study.
If it is successful, this study will show that valproate treatment helps head injured people
manage their moods and allows them to return to families, friends, and work. It will also
show that they drink alcohol less or not at all, improving their health even further. Then
doctors will know that they can use this medicine for large numbers of people who suffer
from head injury and help them to lead normal lives. If the outcome of the study shows that
the medicine works well, doctors can then use this medicine to treat people with head injury
immediately after the study results are published.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: - a history of remote (= 1 year prior to study enrollment) non-penetrating TBI - currently using alcohol - symptoms of affective lability: mood swings, irritability, frustration Exclusion Criteria: - a history of bipolar disorder or anxiety disorder prior to any head injury - a history of head injury in which the cranium was opened either traumatically or surgically - a history of stroke - a history of seizure disorder other than those caused by ethanol withdrawal - evidence of active liver disease - current diagnosis or past history of major psychosis, the alcohol amnesic syndrome, or any type of dementia - current suicidal/homicidal ideations - any medical conditions that would constitute contraindications to treatment with divalproex sodium - currently taking any medications that are known to affect the metabolism of divalproex sodium |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Denver Veteran's Affairs Medical Center | Denver | Colorado |
Lead Sponsor | Collaborator |
---|---|
Paul Saenger |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Reduced Affective Lability | The primary analysis addresses our primary hypothesis that treatment with divalproex sodium will lessen affective lability significantly (p<0.05) as compared to placebo. We will characterize affective lability using discrete variables of presence or extent of symptoms yielded by the Neurobehavioral Rating Scale-Revised (Levin et al., 1990) as well as eight target items from the Agitated Behavior Scale (Bogner et al., 2000). Average intensity and duration of affective lability will be compared between groups. | Study weeks 1-10 | No |
Secondary | Reduced Alcohol Use | The secondary analysis first addresses our secondary hypothesis that treatment with divalproex sodium will lessen quantity and frequency of ethanol use significantly (p<0.05) as compared to placebo in a sample of TBI subjects. We will characterize drinking using the Time Line Follow-Back for Drugs and Alcohol method, developed by Sobell et al (Sobell et al., 1979). | Study weeks 1-10 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05054738 -
CRP and S&A for Inpatient Veterans
|
N/A | |
Completed |
NCT02233738 -
Group Motivational Interviewing (GMI) For Homeless Veterans In VA Services
|
N/A | |
Completed |
NCT05877807 -
Effect of Baclofen to Prevent Post-Traumatic Stress Disorder
|
||
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT00536146 -
The Stress-Hormone System in Alcohol-Dependent Subjects
|
N/A | |
Terminated |
NCT00890149 -
Ondansetron for the Treatment of Heavy Drinking Among Emerging Adults
|
Phase 2 | |
Completed |
NCT02179749 -
Mifepristone Treatment of Alcohol Use Disorder
|
Phase 2 | |
Completed |
NCT02939352 -
The Effects of Theta Burst Stimulation on the Brain Response to Drug and Alcohol Cues
|
Early Phase 1 | |
Terminated |
NCT01408641 -
Topiramate for Alcohol Use in Posttraumatic Stress Disorder
|
N/A | |
Completed |
NCT01553136 -
Varenicline Treatment of Alcohol Dependence in Smokers
|
Phase 2 | |
Completed |
NCT01389297 -
Overcoming Addictions: A Randomized Clinical Trial of a Web Application Based on SMART Recovery
|
N/A | |
Completed |
NCT01760785 -
Valproate for Mood Swings and Alcohol Use Following Head Injury
|
N/A | |
Completed |
NCT00768508 -
Combined Pharmacotherapies for Alcoholism
|
Phase 3 | |
Completed |
NCT01113164 -
Matching Genotypes and Serotonergic Medications for Alcoholism
|
Phase 1 | |
Completed |
NCT00127231 -
Brief Therapy Intervention for Heavy/Hazardous Drinking in HIV-Positive Women
|
N/A | |
Terminated |
NCT02842528 -
Cognitive Vulnerability Factors in Alcohol-dependence
|
N/A | |
Completed |
NCT00367575 -
An Internet-based Intervention for Problem Drinking
|
N/A | |
Completed |
NCT00583440 -
12-step Facilitation for the Dually Diagnosed
|
Phase 1/Phase 2 | |
Completed |
NCT00167687 -
Prazosin Alcohol Dependence IVR Study
|
Phase 4 | |
Completed |
NCT00223639 -
New Medications to Treat Alcohol Dependence
|
Phase 2 |